BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 75 filers reported holding BRIDGEBIO PHARMA INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,949 | -99.9% | 794,401 | -0.3% | 0.08% | -12.4% |
| Q3 2021 | $37,340,000 | -25.5% | 796,668 | -3.1% | 0.09% | -26.4% |
| Q2 2021 | $50,110,000 | -33.9% | 822,018 | -33.2% | 0.12% | -37.3% |
| Q1 2021 | $75,823,000 | -0.7% | 1,230,885 | +14.6% | 0.19% | -4.5% |
| Q4 2020 | $76,370,000 | +231.1% | 1,073,966 | +74.7% | 0.20% | +173.0% |
| Q3 2020 | $23,064,000 | -24.0% | 614,724 | -34.0% | 0.07% | -30.2% |
| Q2 2020 | $30,351,000 | +5.8% | 930,733 | -5.9% | 0.11% | -16.5% |
| Q1 2020 | $28,689,000 | -14.7% | 989,267 | +3.1% | 0.13% | +13.4% |
| Q4 2019 | $33,619,000 | +95.5% | 959,184 | +19.8% | 0.11% | +89.8% |
| Q3 2019 | $17,193,000 | +29.2% | 800,804 | +62.3% | 0.06% | +37.2% |
| Q2 2019 | $13,305,000 | – | 493,342 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $55,099,000 | 39.31% |
| M28 Capital Management LP | 466,200 | $4,233,000 | 4.74% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $282,034,000 | 3.75% |
| Octagon Capital Advisors LP | 933,743 | $8,478,000 | 2.26% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $241,719,000 | 1.11% |
| HHLR ADVISORS, LTD. | 5,362,014 | $48,687,000 | 1.04% |
| Cormorant Asset Management, LP | 1,469,179 | $13,340,000 | 1.01% |
| Knott David M Jr | 213,206 | $1,936,000 | 0.81% |
| Fernwood Investment Management, LLC | 183,900 | $1,670,000 | 0.72% |
| HighVista Strategies LLC | 105,942 | $962,000 | 0.58% |